戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 e, convenient and sustained formulations for topical therapy.
2 py, radiotherapy, intralesional therapy, and topical therapy.
3 oted no pain or discomfort attributed to the topical therapy.
4 ons did not offer any beneficial effect over topical therapy.
5 ty to deploy corrective, mechanism-targeted, topical therapy.
6 re sustained ocular hypertension and require topical therapy.
7 the pathophysiology of acne and pre-existing topical therapies.
8  contributes to individuality in response to topical therapies.
9 was created in C57BL/6 mice, without or with topical therapy, 1% methylprednisolone, 0.025% doxycycli
10 mprovement in PASI score of 33%, with use of topical therapy (60%), biological therapy (66%, mostly a
11 atients with sterile inflammation undergoing topical therapy alone vs invasive procedures (vitreous b
12                              Enhancements in topical therapy and phototherapy have also increased the
13 r, standard chemotherapy, radiation therapy, topical therapies, and interferon-alpha remain the mains
14                                              Topical therapy avoids the morbidity of excisional surge
15  these parameters could lead to new forms of topical therapy for dermatoses (e.g., psoriasis, atopic
16 arations are being examined in the clinic as topical therapy for psoriasis.
17                  Anthralin is a widely used, topical therapy for psoriasis.
18  suggest the potential use of CBD as a novel topical therapy for the treatment of glaucoma.
19 ients with significant nail disease for whom topical therapy has failed, treatment with adalimumab, e
20 he human nail remains a difficult challenge; topical therapy, in particular, is limited by very poor
21                                              Topical therapies including benzoyl peroxide, retinoids,
22                                              Topical therapy including tretinoins, hydroxy acids, ble
23                   Among these products, AgNP topical therapy is proposed for treating patients with u
24 ive percent of relapses were controlled with topical therapy only.
25  months or to control nonsystemic treatment (topical therapies or phototherapy).
26 e accessibility of HPV-associated lesions to topical therapy, our results suggest that large interfer
27                                              Topical therapies reduce systemic exposure, but can be d
28 nts were excluded who were receiving chronic topical therapy, such as glaucoma medications, or had a
29 osine-derived fibers offer the potential for topical therapies that require ultrafast or fast dose-co
30 ave important clinical implications, because topical therapies that target IFN-gamma signaling in ker
31 nvolvement leads to the inappropriate use of topical therapy, the standard of care for causes of cica
32 patients with active disease despite optimum topical therapy to treatment with azathioprine (n=42) or
33                                              Topical therapy was used in 82.7%, and 34.2% received lo
34 or differential effects, intra-articular and topical therapies were superior to oral treatments in re
35 re plaque psoriasis who had not responded to topical therapy were randomly assigned with an interacti
36 ociated with uveitis was seen in response to topical therapy with difluprednate in 78% of eyes with C
37                                              Topical therapy with moderate doses of triamcinolone ace
38 idergic innervation and positive response to topical therapy with SP suggest that SP plays a critical
39        Here using mouse models, we show that topical therapy with tacrolimus, an anti-T-cell immunosu
40 ipants received any antibiotics (systemic or topical therapy) within 1 month before the study.

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。